RA'ANANA, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 6,785,715 ordinary shares (or ordinary share equivalents in lieu t ...

Core Insights - Inspira Technologies has successfully validated its Next-Generation Standalone HYLA™ System, which is designed to operate independently of its existing respiratory support devices, allowing entry into the $50 billion heart-lung surgery market upon clearance [1][4] Group 1: Product Validation and Performance - The HYLA™ optical sensor achieved a 94.2% accuracy in tracking the Partial Pressure of Carbon Dioxide (pCO₂), aligning with clinical needs and demonstrating concordance with gold-standard blood gas analyzers within a 7 mmHg threshold [2][3] - This system provides continuous, non-invasive monitoring of a patient's metabolic status, potentially reducing complications during heart-lung machine and ECMO procedures by eliminating the need for intermittent blood draws [2][3] Group 2: Strategic Market Positioning - By decoupling the HYLA™ sensor from existing life-support hardware, Inspira Technologies is advancing a standalone system that can integrate into any operating room or ICU workflow, significantly expanding its total addressable market [3] - The company is pursuing a high-margin, recurring revenue model through the sale of disposable optical sensors and modular software upgrades, enhancing its long-term growth prospects [3][4] Group 3: Future Plans and Industry Engagement - The CEO of Inspira Technologies indicated that the validation confirms the technology operates at a clinical grade, enabling faster market entry and serving a large global installed base of perfusion systems [4] - The company is moving towards a planned FDA regulatory submission process in 2026, focusing on extracorporeal procedures as an immediate commercial opportunity [4]

RA'ANANA, Israel, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration (the “FDA”)-cleared INSPIRA™ ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center, ranked among the top hospitals in ...

RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders. The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 202 ...

Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologiesRA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outl ...

RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-su ...

Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

Core Viewpoint - Inspira Technologies has announced a proposed two-part transaction involving the acquisition of a liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment, aimed at expanding into the high-growth diagnostics market [1][2]. Equity Investment - The transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's value [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing respiratory and blood monitoring technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business through an all-share transaction, allowing entry into the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical validation studies, indicating its potential to provide meaningful diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with applicability across other oncology indications, and the global liquid biopsy market is projected to reach approximately $58 billion in the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing reimbursement codes for intended clinical use [7]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing respiratory and blood-monitoring platforms for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9].

Core Viewpoint - Inspira Technologies has reaffirmed binding purchase orders totaling $49.5 million, with payment activities set to commence in the 2026 fiscal cycle, aligning with regulatory and deployment milestones [1][2]. Group 1: Purchase Orders and Execution - The company confirmed that the purchase orders remain valid and the distributor plans to advance these orders during 2026 [2]. - The payment framework for the binding purchase orders is structured to align with the company's revenue recognition framework, starting in the 2026 fiscal cycle [2][4]. - The updated schedule reflects necessary regulatory sequencing and technical implementation requirements, which are standard for large-scale healthcare deployments [3]. Group 2: Coordination and Risk Management - Inspira is actively coordinating with distribution partners, regulators, and funding organizations to advance execution milestones and finalize delivery schedules [4]. - This alignment aims to reduce execution risk, enhance operational visibility, and support a phased rollout across target markets [4]. - The company expects to provide updates regarding upcoming execution and deployment milestones [4]. Group 3: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [5]. - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake [5]. - Inspira is also advancing the HYLA™ blood sensor platform, which offers continuous, non-invasive monitoring, positioning the company as an attractive player in the MedTech landscape [5].

Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal c ...